Metabolic Syndrome and Related Disorders · 2022 · 15 citations · 10 references
MedicineNutritional SciencesPharmacologyClinical NutritionHuman NutritionNutritional BiochemistryCardiometabolic Risk ReductionCardiovascular DiseaseMetabolic SyndromeAntioxidant Capacity AssaysCardiometabolic DiseaseMetabolic Therapies
Background: Metabolic syndrome (MetS) is a cluster of central obesity, hypertension, hyperglycemia, and dyslipidemia. It is a global health issue with an increased risk of cardiovascular disease. Recently, a few natural products have been reported with promising anti-inflammatory and antioxidative effects. We aimed to evaluate the impact of δ-tocotrienol and resveratrol mixture (TRM) supplementation on cardiometabolic risk factors and biomarkers in patients with MetS. Methods: A randomized controlled trial was conducted at the hospitals of National University of Medical Sciences Rawalpindi, Pakistan. A total of 82 patients with MetS aged 18–60 years were enrolled based on International Diabetes Federation-2005 diagnostic criteria and randomly grouped into TRM (n = 41) and placebo (n = 41). Patients in the TRM group were given a 400 mg capsule (δ-tocotrienol 250 mg; resveratrol 150 mg), and a placebo (cellulose 400 mg) twice daily for 24 weeks. The biochemical tests were analyzed on ADVIA 1800 Chemistry® analyzer and inflammatory biomarkers by ELISA methods. Results: In the TRM group, a significant reduction in waist circumference, blood pressure, mean (95% confidence interval) of fasting plasma glucose −0.15 mmol/L (−0.22 to −0.08), serum triglyceride −0.32 mmol/L (−0.47 to −0.17), and increment in high-density lipoprotein cholesterol were observed as compared with placebo. TRM supplementation also improved biomarkers: high-sensitive C-reactive protein −0.61 mg/L (−0.89 to −0.33), interleukin-6-1.99 pg/mL (−2.50 to −1.48), tumor necrosis factor-α −2.19 pg/mL (−2.55 to −1.83), malondialdehyde −0.48 μmol/L (−0.65 to −0.30), and total antioxidant capacity 1.71 U/mL (1.29 to 2.13). Conclusion: TRM supplementations improved cardiometabolic risk factors and biomarkers of inflammation and oxidative stress without any significant side effects in the patients with MetS. Clinical Trials Registry: The clinical trial was registered in Sri Lanka Clinical Trials Registry (https://slctr.lk/trials/slctr-2019-021)
10
Justin X. Moore, Ninad S. Chaudhary, Tomi Akinyemiju · Preventing Chronic Disease · 2017 · 950 citations · Full text
Public Health, Population Health Sciences, Public Health Nutrition +13
Bjørn Hildrum, Arnstein Mykletun, Torstein Hole et al. · BMC Public Health · 2007 · 361 citations · Full text
Medicine, Endocrinology, Diabetology +11
Muhammad Zafar Iqbal Hydrie, A. Samad Shera, Asher Fawwad et al. · Metabolic Syndrome and Related Disorders · 2008 · 88 citations
Shima Abdollahi, Amin Salehi‐Abargouei, Omid Toupchian et al. · Phytotherapy Research · 2019 · 57 citations